FDA decisions on new oncological drugs.
作者信息
Benjamin David J, Prasad Vinay, Lythgoe Mark P
出版信息
Lancet Oncol. 2022 May;23(5):585-586. doi: 10.1016/S1470-2045(22)00135-8.
Abstract
摘要
相似文献
1
FDA decisions on new oncological drugs.美国食品药品监督管理局对新型肿瘤药物的审批决定
Lancet Oncol. 2022 May;23(5):585-586. doi: 10.1016/S1470-2045(22)00135-8.
2
FDA decisions on new oncological drugs.美国食品药品监督管理局对新型肿瘤药物的审批决定。
Lancet Oncol. 2022 May;23(5):583-585. doi: 10.1016/S1470-2045(22)00136-X.
3
Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).患者报告结局标签用于美国食品和药物管理局血液学和肿瘤学产品办公室批准的产品（2010-2014 年）。
J Clin Oncol. 2016 Jun 1;34(16):1928-34. doi: 10.1200/JCO.2015.63.6480. Epub 2016 Apr 11.
4
FDA Oncology Center of Excellence Review Processes and Tools.美国食品药品监督管理局卓越肿瘤中心评审流程与工具
Clin Pharmacol Ther. 2020 Sep;108(3):428-429. doi: 10.1002/cpt.1945. Epub 2020 Jul 12.
5
New office and new leader aim to streamline FDA cancer drug review process.新办公室和新领导旨在简化美国食品药品监督管理局（FDA）的癌症药物审评流程。
J Natl Cancer Inst. 2005 May 18;97(10):708-9. doi: 10.1093/jnci/97.10.708.
6
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.FDA 肿瘤卓越中心项目更新：让肿瘤学界参与更新旧肿瘤药物的产品标签。
Clin Cancer Res. 2021 Feb 15;27(4):916-921. doi: 10.1158/1078-0432.CCR-20-3213. Epub 2020 Nov 30.
7
Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016.2011 年至 2016 年间，获得肿瘤学适应证的疗法向 FDA 提交上市后要求的完成情况。
JAMA Oncol. 2018 Jul 1;4(7):993-994. doi: 10.1001/jamaoncol.2018.0610.
8
9
Trials of a cancer doc. Experimental drugs and a 20-year fight with the FDA.一位癌症医生的试验。实验药物以及与美国食品药品监督管理局长达20年的斗争。
US News World Rep. 1998 Oct 5;125(13):28-30, 32, 35.
10
Enrollment of older adults on oncology trials: An FDA perspective.老年成年人参与肿瘤学试验：美国食品药品监督管理局的观点。
J Geriatr Oncol. 2017 May;8(3):149-150. doi: 10.1016/j.jgo.2016.11.001. Epub 2016 Dec 23.
引用本文的文献
1
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
2
Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study.2015年至2024年中国优先审评创新抗癌药物的监管与临床结果：一项观察性研究
BMC Cancer. 2025 Jul 15;25(1):1175. doi: 10.1186/s12885-025-14580-4.
3
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?根据PEARLS/Keynote-091的FDA批准适应症，对于已切除的IB至IIIA期非小细胞肺癌，在不考虑PD-L1表达水平、ALK/EGFR突变状态和既往辅助化疗的情况下，分期作为辅助帕博利珠单抗的唯一“生物标志物”？
Lung Cancer (Auckl). 2023 Dec 12;14:101-109. doi: 10.2147/LCTT.S433195. eCollection 2023.
4
Review time of oncology drugs and its underlying factors: an exploration in China.中国肿瘤药物审评时间及其潜在因素探究
Front Pharmacol. 2023 Nov 1;14:1151784. doi: 10.3389/fphar.2023.1151784. eCollection 2023.
Zotero 插件